NCT03137537View on ClinicalTrials.gov

Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.

PHASE2TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

November 18, 2020

Study Completion Date

November 18, 2020

Conditions
LymphomaAutonomic ImbalanceCancer Survivorship
Interventions
DRUG

Ivabradine

lower heart rate in heart failure patients.

DRUG

Placebo Oral Tablet

Procedure prescribed to compare the active effect of a medicine.

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Boston Children Hospital, Boston

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03137537 - Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy. | Biotech Hunter | Biotech Hunter